Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $1.5 million.

  • Seres Therapeutics' Other Accumulated Expenses fell 7737.74% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 7737.74%. This contributed to the annual value of $2.2 million for FY2024, which is 2196.97% down from last year.
  • Seres Therapeutics' Other Accumulated Expenses amounted to $1.5 million in Q3 2025, which was down 7737.74% from $1.0 million recorded in Q2 2025.
  • In the past 5 years, Seres Therapeutics' Other Accumulated Expenses ranged from a high of $8.0 million in Q2 2023 and a low of $1.0 million during Q2 2025
  • For the 5-year period, Seres Therapeutics' Other Accumulated Expenses averaged around $3.3 million, with its median value being $2.8 million (2023).
  • As far as peak fluctuations go, Seres Therapeutics' Other Accumulated Expenses skyrocketed by 34803.04% in 2023, and later tumbled by 7737.74% in 2025.
  • Seres Therapeutics' Other Accumulated Expenses (Quarter) stood at $3.6 million in 2021, then rose by 0.3% to $3.6 million in 2022, then dropped by 23.93% to $2.8 million in 2023, then fell by 21.97% to $2.2 million in 2024, then crashed by 30.05% to $1.5 million in 2025.
  • Its Other Accumulated Expenses was $1.5 million in Q3 2025, compared to $1.0 million in Q2 2025 and $2.6 million in Q1 2025.